Empagliflozin reduces mortality and hospitalisation for heart failure irrespective of cardiovascular risk score at baseline

Back

ESC Premium Access

Empagliflozin reduces mortality and hospitalisation for heart failure irrespective of cardiovascular risk score at baseline

Session: Poster Session 2 - Cardiovascular risk and its modification

Topic: Antidiabetic Pharmacotherapy

Speaker: Doctor D. Fitchett (Toronto, CA)

Event: ESC Congress 2018

Congress Presentation

Add to my library

About the speaker

Doctor David Fitchett

St. Michael's Hospital, Toronto (Canada)

18 presentations

0 follower

5 more presentations in this session

Sex-specific analysis on efficacy and safety of statins: a systematic review and quantitative meta-analysis

Speaker: Miss M. Schreuder (Rotterdam, NL)

Access

Abstract

Slides

Changes in plasma lipid species following pravastatin treatment predict cardiovascular outcomes and represent a measure of the relative risk reduction in secondary prevention

Speaker: Professor P. Meikle (Melbourne, AU)

Access

Abstract

Slides

Empagliflozin reduces mortality in patients with type 2 diabetes and a history of left ventricular hypertrophy: a sub-analysis of the EMPA-REG OUTCOME trial

Speaker: Professor S. Verma (Toronto, CA)

Access

Abstract

LDL-C treatment patterns and associated outcomes in patients with type 2 diabetes and CVD: insights from TECOS

Speaker: Professor G. De Ferrari (Turin, IT)

Access

Abstract

Slides

Reduction in systolic blood pressure with semaglutide treatment is not due to weight loss alone: data from SUSTAIN 1-5

Speaker: Professor S. Bain (Swansea, GB)

Access

Abstract

Slides

Access the full session

Poster Session 2 - Cardiovascular risk and its modification

Speakers: Doctor D. Fitchett, Miss M. Schreuder, Professor P. Meikle, Professor S. Verma, Professor G. De Ferrari...

Access

About the event

ESC Congress 2018

25 August - 29 August 2018

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources